These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 17239675)

  • 1. Do endocrine treatments for breast cancer have a negative impact on lipid profiles and cardiovascular risk in postmenopausal women?
    Lewis S
    Am Heart J; 2007 Feb; 153(2):182-8. PubMed ID: 17239675
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative assessment of lipid effects of endocrine therapy for breast cancer: implications for cardiovascular disease prevention in postmenopausal women.
    Esteva FJ; Hortobagyi GN
    Breast; 2006 Jun; 15(3):301-12. PubMed ID: 16230014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of anastrozole and tamoxifen on lipid metabolism in Japanese postmenopausal women with early breast cancer.
    Sawada S; Sato K; Kusuhara M; Ayaori M; Yonemura A; Tamaki K; Hiraide H; Mochizuki H; Ohsuzu F
    Acta Oncol; 2005; 44(2):134-41. PubMed ID: 15788292
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence and management of side effects associated with aromatase inhibitors in the adjuvant treatment of breast cancer in postmenopausal women.
    Mouridsen HT
    Curr Med Res Opin; 2006 Aug; 22(8):1609-21. PubMed ID: 16870085
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A woman's heart: the impact of adjuvant endocrine therapy on cardiovascular health.
    Ewer MS; Glück S
    Cancer; 2009 May; 115(9):1813-26. PubMed ID: 19235248
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aromatase inhibitors and cardiac toxicity: getting to the heart of the matter.
    Gandhi S; Verma S
    Breast Cancer Res Treat; 2007 Nov; 106(1):1-9. PubMed ID: 17211535
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Choosing early adjuvant therapy for postmenopausal women with hormone-sensitive breast cancer: aromatase inhibitors versus tamoxifen.
    Carpenter R
    Eur J Surg Oncol; 2008 Jul; 34(7):746-55. PubMed ID: 18296017
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety of adjuvant endocrine therapy in postmenopausal women with breast cancer.
    Abdulhaq H; Geyer C
    Am J Clin Oncol; 2008 Dec; 31(6):595-605. PubMed ID: 19060594
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Menopausal symptoms and adjuvant therapy-associated adverse events.
    Hadji P
    Endocr Relat Cancer; 2008 Mar; 15(1):73-90. PubMed ID: 18310277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk reduction of distant metastasis in hormone-sensitive postmenopausal breast cancer.
    Toi M; Yamashiro H; Tsuji W
    Breast Cancer; 2009; 16(3):207-18. PubMed ID: 19259765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimizing aromatase inhibitor integration into initial treatment strategies in postmenopausal women with hormone-receptor-positive early breast cancer.
    Chlebowski RT
    Breast Cancer Res Treat; 2008 Dec; 112 Suppl 1():25-34. PubMed ID: 19101792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma lipids and lipoprotein alterations in tamoxifen-treated breast cancer women in relation to the menopausal status.
    Ilanchezhian S; Thangaraju M; Sachdanandam P
    Cancer Biochem Biophys; 1995 Nov; 15(2):83-90. PubMed ID: 8590439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Breast cancer adjuvant endocrine therapy.
    Cigler T; Goss PE
    Cancer J; 2007; 13(3):148-55. PubMed ID: 17620763
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Breast International Group 1-98 trial: big results for women with hormone-sensitive early breast cancer.
    Monnier AM
    Expert Rev Anticancer Ther; 2007 May; 7(5):627-34. PubMed ID: 17492927
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 Study.
    Kaufmann M; Jonat W; Hilfrich J; Eidtmann H; Gademann G; Zuna I; von Minckwitz G
    J Clin Oncol; 2007 Jul; 25(19):2664-70. PubMed ID: 17563395
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anastrozole.
    Kelly CM; Buzdar AU
    Expert Opin Drug Saf; 2010 Nov; 9(6):995-1003. PubMed ID: 20923259
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of third-generation aromatase inhibitors and tamoxifen in the adjuvant treatment of postmenopausal patients with hormone-dependent breast cancer: evidence based review.
    Poole R; Paridaens R
    Curr Opin Oncol; 2007 Nov; 19(6):564-72. PubMed ID: 17906453
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of aromatase inhibitors on lipids and thrombosis.
    Bundred NJ
    Br J Cancer; 2005 Aug; 93 Suppl 1(Suppl 1):S23-7. PubMed ID: 16100522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trial.
    Mouridsen H; Keshaviah A; Coates AS; Rabaglio M; Castiglione-Gertsch M; Sun Z; Thürlimann B; Mauriac L; Forbes JF; Paridaens R; Gelber RD; Colleoni M; Smith I; Price KN; Goldhirsch A
    J Clin Oncol; 2007 Dec; 25(36):5715-22. PubMed ID: 17998546
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in adjuvant endocrine therapy for postmenopausal women.
    Lin NU; Winer EP
    J Clin Oncol; 2008 Feb; 26(5):798-805. PubMed ID: 18258989
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.